MedTrace Logo

Pharmacogenomics-Supported Psychotropic Prescribing Trial

NCT06929533 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-09-08

No results posted yet for this study

Summary

Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.

Conditions

  • Mental Disorder
  • Pharmacogenetics
  • Adverse Drug Reaction (ADR)
  • Effectiveness

Interventions

DIAGNOSTIC_TEST

Pharmacogenetic Testing

Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.

Sponsors & Collaborators

  • University of Calgary

    collaborator OTHER

  • Shared Health Manitoba

    collaborator UNKNOWN

  • Winnipeg Regional Health Authority

    collaborator OTHER

  • Health Sciences Centre, Winnipeg, Manitoba

    collaborator OTHER

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Abdullah Al Maruf, PhD, M.Pharm., B.Pharm · University of Manitoba

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2028-12-31
Completion
2030-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06929533 on ClinicalTrials.gov